This post was originally published on this site
https://i-invdn-com.akamaized.net/news/LYNXNPEC3B0CQ_M.jpg
MOTS’ stock has lost 3.5% over the past three months to close Friday’s trading session at $1.39. It is currently trading 49.3% below its $2.74 52-week high and much below its $10.50 all-time high, which it hit on July 1, 2018.
The company had an unimpressive market debut in 2018, and it has failed to generate a profit so far. So, even as the healthcare industry overall is expected to see decent growth this year and beyond, we think it’s wise to avoid MOTS now.
